DALLAS, Sept. 3, 2009 (GLOBE NEWSWIRE) -- Kendall Law Group, led by a former federal judge and former U.S. Attorney, announces an investigation on behalf of Sepracor Inc. shareholders (Nasdaq:SEPR) in connection with the tender offer made by Dainippon Sumitomo Pharma Co. of Japan.

The firm's investigation concerns Dainippon's announcement that it will acquire Sepracor Inc. for almost $2.6 billion. Sepracor shareholders will be offered $23 per share through a tender offer starting no later than September 15, 2009. Sepracor is a research-based pharmaceutical company. The company expects the FDA to rule on Sepracor's epilepsy drug Stedesa by the end of January, 2010. However, the boards of both companies have planned to close the acquisition during the fourth quarter of 2009.

Kendall Law Group has nationwide experience representing investors in mergers and acquisitions. For information about your rights as a Sepracor shareholder, contact attorney Hamilton Lindley at 877-744-3728 or by email at hlindley@kendalllawgroup.com.

The Kendall Law Group, LLP logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6273

CONTACT:  Kendall Law Group, LLP
          Hamilton Lindley
          (877) 744-3728
          (214) 744-3000
          Fax: (214) 744-3015
          hlindley@kendalllawgroup.com
          3232 McKinney, Ste. 700
          Dallas, TX 75204
          www.kendalllawgroup.com